FDA Approves Tecvayli®/Darzalex Faspro® Combination for Relapsed/Refractory Multiple Myeloma
HALO sits 41% above its 52-week low of $47.5.
Summary
The U.S. FDA has approved Tecvayli® in combination with Darzalex Faspro® for relapsed/refractory multiple myeloma. This is a significant positive development for Halozyme Therapeutics, as Darzalex Faspro utilizes Halozyme's proprietary ENHANZE® drug delivery technology. The expanded approval for this combination therapy broadens the market for a key partnered product, which is expected to drive increased royalty revenue for Halozyme. This new regulatory milestone was not previously disclosed in recent filings or news, making it fresh and actionable information for traders. Investors will watch for updated guidance on royalty expectations from this expanded indication.
At the time of this announcement, HALO was trading at $67.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9B. The 52-week trading range was $47.50 to $82.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.